Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Beginning Cash Balance (2023)

C4 Therapeutics' Beginning Cash Balance history spans 1 years, with the latest figure at $11.0 million for Q3 2023.

  • For Q3 2023, Beginning Cash Balance changed N/A year-over-year to $11.0 million; the TTM value through Jun 2024 reached $11.0 million, up 633.33%, while the annual FY2023 figure was $12.5 million, N/A changed from the prior year.
  • Beginning Cash Balance reached $11.0 million in Q3 2023 per CCCC's latest filing, up from $750000.0 in the prior quarter.
  • In the past five years, Beginning Cash Balance ranged from a high of $11.0 million in Q3 2023 to a low of $750000.0 in Q1 2023.